Stocks making the biggest moves in the premarket: Nike, Okta, Alibaba and more

Stocks making the biggest moves in the premarket: Nike, Okta, Alibaba and more


Take a look at some of the biggest movers in the premarket:

Nike (NKE) – Nike reported quarterly profit of 87 cents per share, 16 cents a share above estimates. Revenue beat estimates as well, helped by an increase in digital sales and its ability to successfully navigate supply chain issues. Nike jumped 6.3% in the premarket, and its results also boosted shares of rival Foot Locker (FL) by 1.4%.

Okta (OKTA) – Okta is investigating reports of a digital breach, with the authentication services provider saying it would provide more information when it becomes available. Okta shares slid 6.3% in premarket trading.

Alibaba (BABA) – Alibaba increased its share buyback program to $25 billion, the largest ever for the China-based e-commerce giant. The move follows a slump in the stock’s price on regulatory and growth concerns. Alibaba surged 8% in premarket action.

Altria (MO) – The tobacco producer’s shares rose 1.2% in the premarket after Goldman upgraded Altria to “buy” from “neutral.” Goldman pointed to Altria’s strong cash flow, high profit margins and attractive dividend amid a current “risk-off” environment.

Tencent Music (TME) – Tencent Music rallied 4.5% in premarket trading after the entertainment services company reported better-than-expected quarterly earnings and said it would pursue a secondary listing on the Hong Kong Stock Exchange.

Switch (SWCH) – Switch remains on watch following a Bloomberg report that the data center operator was exploring options including a possible sale of the company. Switch has risen for the past five trading sessions, gaining 11% over that stretch.

Upstart Holdings (UPST) – The cloud-based lending platform operator was downgraded to “underperform” from “neutral” at Wedbush, which cited Upstart’s dependence on third-party funding as well as macroeconomic risks. Upstart slid 3.6% in premarket action.

Canadian Pacific Railway (CP) – Canadian Pacific and its workers agreed to binding arbitration to resolve their labor dispute, allowing operations to resume after a weekend lockout.

Paramount (PGRE) – The office-centered real estate investment trust saw its shares rise 1.9% in the premarket after it rejected a takeover offer from asset management firm Monarch Alternative Capital. Paramount said the $12 per share offer significantly undervalues the company but said it remains open to any ideas that enhance shareholder value.



Source

Stocks making the biggest moves premarket: Applied Digital, Meta Platforms, Boeing & more
Finance

Stocks making the biggest moves premarket: Applied Digital, Meta Platforms, Boeing & more

Check out the companies making the biggest moves premarket: Applied Digital — Shares rose more than 1% in the premarket after the company announced it would spin off its cloud business and combine it with Ekso Bionics . Shares of the latter company, which has a market cap of just $18.5 million, rallied 51%. Meta […]

Read More
China EVs in 2026 look less like a boom and more like a survival test as global expansion ramps up
Finance

China EVs in 2026 look less like a boom and more like a survival test as global expansion ramps up

Key Points China’s new energy vehicle market is set to see more price competition next year as overall growth slows, analysts predict. Domestic saturation is pushing Chinese automakers such as BYD to expand overseas, including opening local factories. Foreign carmakers still see opportunity, but competition is tightening fast. Source

Read More
Stocks making the biggest moves midday: Nvidia, Ultragenyx Pharmaceutical, Newmont, DigitalBridge & more
Finance

Stocks making the biggest moves midday: Nvidia, Ultragenyx Pharmaceutical, Newmont, DigitalBridge & more

Check out some of the stocks making the biggest moves in midday trading. Ultragenyx Pharmaceutical – Shares cratered more than 40% after Ultragenyx announced that its bone disease drug setrusumab fell short of expectations in two trials. “Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates,” […]

Read More